Repositioning study of flubendazol for the treatment of lung cancer and meningoencephalitis using oral lipid nanosystem

• Grant number: 20/15981-0
• Support Opportunities: Scholarships abroad - Research Internship - Doctorate
• Start date: November 25, 2021
• End date: May 24, 2022
• Field of knowledge: Health Sciences - Pharmacy - Pharmaceutical Technology
• Principal Investigator: Nádia Araci Bou-Chacra
• Grantee: Megumi Nishitani Yukuyama
• Supervisor: Raimar Lobenberg
• Host Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
• Institution abroad: University of Alberta, Canada
• Associated to the scholarship: 18/22713-2 - Study of Flubendazole repositioning for the treatment of lung cancer and MENINGOENCEFALITE employing oral lipid nanosystem, BP.DR

Abstract

Flubendazole (FLZ), a Class II drug of the Biopharmaceutical Drug Classification system (BCS), offers new prospective as drug repositioning for the treatment of lung cancer and criptococcal meningites. For this poorly-water-soluble drug, nanoemulsion (NE) is a promising alternative to overcome its limitation: using the D-Phase Emulsification (DPE) process, a high-oil content FLZ-loaded NE has been successfully developed for this purpose. However, an adequate in vitro bioavailability test for NE is lacking to assess the dissolution profile of different factors that may influence the oral efficacy of this FLZ-loaded NE. In recent years, Dr. Löbenberg's team at the University of Alberta (Canada) has developed several exploratory experiments, aiming to overcome the limitations of current dissolution methods, such as the modified cylinder method and biphasic dissolution method. Considering these innovative approaches, we aim to develop a new discriminatory method to evaluate the dissolution profile of FLZ in NE preparations. A comprehensive ternary phase diagram will be applied to evaluate different factors of preparations under the DPE process, which may influence the performance of drug dissolution. This study will provide further insights in in vitro drug release from NE, one of the prominent nanotechnologies. (AU)

Scientific publications

(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)

YUKUYAMA, MEGUMI NISHITANI; ZUO, JIEYU; PARK, CHULHUN; YOUSEF, MALAZ; BAZAN HENOSTROZA, MIRLA ANALI; BARROS DE ARAUJO, GABRIEL LIMA; BOU-CHACRA, NADIA ARACI; LOBENBERG, RAIMAR. Biphasic dissolution combined with modified cylinder method-A new promising method for dissolution test in drug-loaded nanoemulsions. International Journal of Pharmaceutics, v. 632, p. 9-pg., 2023-01-06. (18/22713-2, 20/15981-0, 19/04998-2, 17/08332-3)

YUKUYAMA, MEGUMI NISHITANI; FERREIRA GUIMARAES, LARA MENDES; SEGOVIA, RAFAEL SCHELIGA; LAMEU, CLAUDIANA; BARROS DE ARAUJO, GABRIEL LIMA; LOBENBERG, RAIMAR; DE SOUZA, ALINE; BAZAN HENOSTROZA, MIRLA ANALI; FOLCHINI, BEATRIZ RABELO; PERONI, CAMILLA MIDORI; et al. Malignant wound-The influence of oil components in flubendazole-loaded nanoemulsions in A549 lung cancer xenograft-bearing mice. JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, v. 78, p. 10-pg., 2022-11-12. (18/22713-2, 20/15981-0, 19/04998-2, 15/19128-2)